Benzinga | Jun 2, 2021 08:39AM EDT

Credit Suisse Maintains Outperform on Abbott Laboratories, Lowers Price Target to $120

Credit Suisse analyst Matt Miksic maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $133 to $120.